Stocks and Investing
Stocks and Investing
Tue, May 14, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Joseph Stringer Reiterated (CARA) at Strong Buy and Held Target at $5 on, May 14th, 2024
Joseph Stringer of Needham, Reiterated "Cara Therapeutics, Inc." (CARA) at Strong Buy and Held Target at $5 on, May 14th, 2024.
Joseph has made no other calls on CARA in the last 4 months.
There is 1 other peer that has a rating on CARA. Out of the 1 peers that are also analyzing CARA, 0 agree with Joseph's Rating of Hold.
This is the rating of the analyst that currently disagrees with Joseph
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $10 on, Wednesday, March 6th, 2024
Contributing Sources